Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zevra Therapeutics (ZVRA) Other Operating Expenses (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Other Operating Expenses for 7 consecutive years, with $148.3 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Other Operating Expenses changed N/A year-over-year to $148.3 million, compared with a TTM value of $148.3 million through Dec 2025, changed N/A, and an annual FY2025 reading of $148.3 million, changed N/A over the prior year.
  • Other Operating Expenses was $148.3 million for Q2 2025 at Zevra Therapeutics, up from $144000.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $148.3 million in Q2 2025 and bottomed at $8000.0 in Q1 2022.
  • Average Other Operating Expenses over 4 years is $18.7 million, with a median of $211000.0 recorded in 2022.
  • The sharpest move saw Other Operating Expenses skyrocketed 3050.0% in 2021, then crashed 99.2% in 2022.
  • Year by year, Other Operating Expenses stood at $59000.0 in 2021, then surged by 257.63% to $211000.0 in 2022, then plummeted by 31.75% to $144000.0 in 2023, then surged by 102903.47% to $148.3 million in 2025.
  • Business Quant data shows Other Operating Expenses for ZVRA at $148.3 million in Q2 2025, $144000.0 in Q3 2023, and $211000.0 in Q4 2022.